Thin-film drug delivery

Results: 14



#Item
1Medication Guide TM BELBUCA (bel-BUE-kuh) (buprenorphine) buccal film, CIII BELBUCA is:  A strong prescription pain medicine that contains an opioid (narcotic) that is used to manage pain severe enough to

Medication Guide TM BELBUCA (bel-BUE-kuh) (buprenorphine) buccal film, CIII BELBUCA is:  A strong prescription pain medicine that contains an opioid (narcotic) that is used to manage pain severe enough to

Add to Reading List

Source URL: www.endo.com

Language: English - Date: 2016-08-12 13:27:47
2Journal of Pharmaceutics & Drug Development Volume 3 | Issue 3 ISSN: Review Article Open Access

Journal of Pharmaceutics & Drug Development Volume 3 | Issue 3 ISSN: Review Article Open Access

Add to Reading List

Source URL: www.annexpublishers.com

Language: English - Date: 2015-05-27 22:26:16
3International Scholarly Research Network ISRN Pharmaceutics Volume 2012, Article ID[removed], 9 pages doi:[removed][removed]Review Article

International Scholarly Research Network ISRN Pharmaceutics Volume 2012, Article ID[removed], 9 pages doi:[removed][removed]Review Article

Add to Reading List

Source URL: downloads.hindawi.com

Language: English - Date: 2014-08-14 20:34:19
4PRESS RELEASE Cynapsus Therapeutics Announces Hiring of New Chief Scientific Officer and EVP, CMC October 7, 2014 TORONTO, CANADA – (Marketwired) – Cynapsus Therapeutics (CTH: TSXV) (CYNAF: OTCQX), a specialty pharma

PRESS RELEASE Cynapsus Therapeutics Announces Hiring of New Chief Scientific Officer and EVP, CMC October 7, 2014 TORONTO, CANADA – (Marketwired) – Cynapsus Therapeutics (CTH: TSXV) (CYNAF: OTCQX), a specialty pharma

Add to Reading List

Source URL: www.biotech.ca

Language: English - Date: 2014-10-15 09:40:48
5Pediatric Dosage Development: Where Are We? Julia C. Pinto, Ph.D. Acting Branch Chief, Division III, Branch VIII Office of New Drug Quality Assessment, CDER, FDA

Pediatric Dosage Development: Where Are We? Julia C. Pinto, Ph.D. Acting Branch Chief, Division III, Branch VIII Office of New Drug Quality Assessment, CDER, FDA

Add to Reading List

Source URL: www.fda.gov

Language: English
6Microsoft Word - suboxone-0313.docx

Microsoft Word - suboxone-0313.docx

Add to Reading List

Source URL: www.mass.gov

Language: English - Date: 2014-03-22 09:25:34
7Clinical Pharmacology Issues with Pediatric Formulations

Clinical Pharmacology Issues with Pediatric Formulations

Add to Reading List

Source URL: www.fda.gov

Language: English
8Some Challenges in the Development of Pediatric Formulations Mansoor A. Khan, R.Ph., Ph.D.

Some Challenges in the Development of Pediatric Formulations Mansoor A. Khan, R.Ph., Ph.D.

Add to Reading List

Source URL: www.fda.gov

Language: English
9HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use ZUPLENZ® safely and effectively. See full prescribing information for ZUPLENZ. ZUPLENZ (ondansetron) Oral Soluble F

HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use ZUPLENZ® safely and effectively. See full prescribing information for ZUPLENZ. ZUPLENZ (ondansetron) Oral Soluble F

Add to Reading List

Source URL: www.accessdata.fda.gov

Language: English - Date: 2013-10-31 17:25:06
10State of Vermont Department of Vermont Health Access 312 Hurricane Lane, Suite 201 Williston, VT[removed]http://dvha.vermont.gov

State of Vermont Department of Vermont Health Access 312 Hurricane Lane, Suite 201 Williston, VT[removed]http://dvha.vermont.gov

Add to Reading List

Source URL: dvha.vermont.gov

Language: English - Date: 2013-05-21 21:10:49